FDA cites Pfizer on Lipitor web page; FDA warns on allergic reactions to Merck antipsychotic;

@FiercePharma: Tarceva's new European OK points up Roche's targeted goals. Item | Follow @FiercePharma

> The FDA has scolded Pfizer ($PFE) for links off its Lipitor website leading to product info on the cardiovascular drugs Norvasc and Caduet and the stop-smoking treatment Chantix. Report

> Merck's ($MRK) antipsychotic drug Saphris can trigger serious allergic reactions, the FDA warned; the drug's label has been changed accordingly. Article

> Lupin has struck a deal to market and distribute Sanofi's ($SNY) antipsychotic Solian and insomnia remedy Stilnox in the Philippines through its domestic unit Multicare Pharmaceuticals. Story

> Merck KGaA's cancer treatment Erbitux and Novartis' ($NVS) multiple sclerosis drug Gilenya won spots on Australia's formulary of subsidized medicines. Piece

> South Africa's Aspen Pharmacare, 19%-owned by GlaxoSmithKline ($GSK), expects to beat analyst estimates with a 22% profit rise for its full fiscal year. Report

> Pfizer ($PFE) extended its Icagen offer by another 18 hours as it looks to eke out a tender-offer victory; only 39,799 more shares to go. News

> Merck ($MRK) wrapped up an addition and expansion at its animal vaccine facility in Elkhorn, NE. Item

Biotech News

@FierceBiotech: Synageva inks orphan drug R&D deal with Mitsubishi Tanabe Pharma, grabs $3M upfront. News | Follow @FierceBiotech

@JohnCFierce: Oxigene says it still can't raise cash, has to lay off more people. Going, going.... Report | Follow @JohnCFierce

@RyanMFierce: Would the extra 60-day filing period for FDA reviews of new drugs actually bring the treatments to market sooner? | Follow @RyanMFierce

> Merck Serono opens doors at R&D shop in Beijing. Details

> Genzyme gives back drug rights to PTC Therapeutics. News

> FDA, industry seek extended reviews for new drugs. Article

> Mitsubishi Tanabe Pharma taps Synageva for orphan disease R&D. Report

> September is Fierce. Mark your calendars now. Piece

And Finally... Prescribing rates for children's antibiotics are dropping, but not quickly enough for the CDC. Report

Suggested Articles

In a trial called Empacta, Roche's IL-6 inhibitor cut ventilator use, but didn't significantly cut the risk of death in COVID-19 pneumonia patients.

Officials in New York charged Johnson & Johnson with violating insurance laws with its opioid marketing.

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.